Antitumor synergy with SY-1425, a selective RARα agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia.

Acute myeloid leukemia (AML) and biologically related myelodysplastic syndrome (MDS)[1][1] are hematologic malignancies with poor outcomes. While recent approvals of new targeted therapies have increased options for some patients, those unfit for intensive treatment have few options,[2][2]–[4][3]